American Cancer Society (n.d.) Key statistics for ovarian cancer. https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Accessed 12 Jan 2023

Hu TWY, Nie D, Gou JH, Li ZY (2018) Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. Cancer Manag Res 10:2019–2030

Article  Google Scholar 

National Comprehensive Cancer Network (n.d.) NCCN guidelines. Ovarian cancer https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 12 Jan 2023

Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL (1995) Ovarian cancer: staging with CT and MR imaging. Radiology 197:619–626

Article  CAS  Google Scholar 

Nougaret S, Addley HC, Colombo PE et al (2012) Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics 32:1775–1800 discussion 1800-1773

Article  Google Scholar 

Forstner R, Meissnitzer M, Cunha TM (2016) Update on imaging of ovarian cancer. Curr Radiol Rep 4:31

Article  Google Scholar 

Khiewvan B, Torigian DA, Emamzadehfard S et al (2017) An update on the role of PET/CT and PET/MRI in ovarian cancer. European journal of nuclear medicine and molecular imaging 44:1079–1091

Article  CAS  Google Scholar 

Feng Z, Liu S, Ju X et al (2021) Diagnostic accuracy of (18)F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. Quant Imaging Med Surg 11:3392–3398

Article  Google Scholar 

Rusu G, Achimaș-Cadariu P, Piciu A, Căinap SS, Căinap C, Piciu D (2021) A comparative study between 18F-FDG PET/CT and conventional imaging in the evaluation of progressive disease and recurrence in ovarian carcinoma. Healthcare (Basel) 9(6):666

Forstner R (2021) Imaging of ovarian cancer: from early detection to post-treatment relapse. EMJ Radiol:21–00086

Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29–40

Article  CAS  Google Scholar 

Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA (1979) 1-Aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med 20:1055–1061

CAS  Google Scholar 

Okudaira H, Oka S, Ono M et al (2014) Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol 16:756–764

Article  Google Scholar 

Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266

Article  CAS  Google Scholar 

Kaira K, Nakamura K, Hirakawa T et al (2015) Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. Am J Transl Res 7:1161–1171

Google Scholar 

Sato K, Miyamoto M, Takano M, Furuya K, Tsuda H (2019) Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Archiv 474:701–710

Article  CAS  Google Scholar 

Guo H, Xu Y, Wang F et al (2018) Clinical associations between ASCT2 and p-mTOR in the pathogenesis and prognosis of epithelial ovarian cancer. Oncol Rep 40:3725–3733

CAS  Google Scholar 

Lapela M, Leskinen-Kallio S, Varpula M et al (1995) Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 36:2196–2200

CAS  Google Scholar 

Schuster DM, Nieh PT, Jani AB et al (2014) Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 191:1446–1453

Article  Google Scholar 

Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 48:1017–1020

Article  CAS  Google Scholar 

Lovrec P, Schuster DM, Wagner RH, Gabriel M, Savir-Baruch B (2020) Characterizing and mitigating bladder radioactivity on (18)F-fluciclovine PET/CT. J Nucl Med Technol 48:24–29

Article  Google Scholar 

Andriole GL, Kostakoglu L, Chau A et al (2018) The impact of positron emission tomography with (18)F-fluciclovine on the management of patients with biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 201(2):322–331

Article  Google Scholar 

Robertson MS, Sakellis CG, Hyun H, Jacene HA (2020) Extraprostatic uptake of (18)F-fluciclovine: differentiation of nonprostatic neoplasms from metastatic prostate cancer. AJR Am J Roentgenol 214:641–648

Article  Google Scholar 

Savir-Baruch B, Zanoni L, Schuster DM (2018) Imaging of prostate cancer using fluciclovine. Urol Clin North Am 45:489–502

Article  Google Scholar 

Savir-Baruch B, Banks KP, McConathy JE et al (2018) ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin Nucl Med 43:909–917

Article  Google Scholar 

Tade FI, Sajdak RA, Gabriel M, Wagner RH, Savir-Baruch B (2019) Best practices for (18)F-fluciclovine PET/CT imaging of recurrent prostate cancer: a guide for technologists. J Nucl Med Technol 47:282–287

Article  Google Scholar 

PYLARIFY® (piflufolastat F 18) injection, for intravenous use initial U.S. approval: 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf. Accessed 12 Jan 2023

CERIANNA™ (fluoroestradiol F 18) injection, for intravenous use initial U.S. approval: 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf. Accessed 12 Jan 2023

NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection), for intravenous use initial U.S. approval: 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208547s000lbl.pdf. Accessed 12 Jan 2023

Schuster D, Votaw J, Nieh P et al (2007) Initial experience with the radiotracer anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 48:56–63

CAS  Google Scholar 

Dendl K, Koerber SA, Finck R et al (2021) (68)Ga-FAPI-PET/CT in patients with various gynecological malignancies. Eur J Nucl Med Mol Imaging 48:4089–4100

Article  CAS  Google Scholar